Emma Walmsley Acquires 7 Shares of GlaxoSmithKline plc (LON:GSK) Stock

GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley acquired 7 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was purchased at an average price of GBX 1,726 ($22.70) per share, with a total value of £120.82 ($158.93).

Emma Walmsley also recently made the following trade(s):

  • On Friday, January 10th, Emma Walmsley acquired 7 shares of GlaxoSmithKline stock. The stock was purchased at an average price of GBX 1,800 ($23.68) per share, with a total value of £126 ($165.75).
  • On Tuesday, December 10th, Emma Walmsley acquired 8 shares of GlaxoSmithKline stock. The stock was purchased at an average price of GBX 1,731 ($22.77) per share, with a total value of £138.48 ($182.16).

Shares of GlaxoSmithKline stock opened at GBX 1,668.60 ($21.95) on Friday. GlaxoSmithKline plc has a 1 year low of GBX 1,485.20 ($19.54) and a 1 year high of GBX 1,857 ($24.43). The firm has a market cap of $83.73 billion and a PE ratio of 18.02. The company has a debt-to-equity ratio of 166.19, a current ratio of 0.81 and a quick ratio of 0.51. The company has a 50 day simple moving average of GBX 1,786.22 and a two-hundred day simple moving average of GBX 1,726.11.

The business also recently announced a dividend, which will be paid on Thursday, April 9th. Shareholders of record on Thursday, February 20th will be given a dividend of GBX 23 ($0.30) per share. The ex-dividend date is Thursday, February 20th. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. This represents a yield of 1.32%. GlaxoSmithKline’s payout ratio is presently 0.99%.

A number of research firms have recently commented on GSK. Goldman Sachs Group restated a “buy” rating and issued a GBX 1,900 ($24.99) price objective on shares of GlaxoSmithKline in a research report on Wednesday, February 5th. Societe Generale cut their price objective on shares of GlaxoSmithKline from GBX 2,300 ($30.26) to GBX 2,240 ($29.47) and set a “buy” rating for the company in a research report on Thursday. Bryan, Garnier & Co cut their price objective on shares of GlaxoSmithKline from GBX 1,800 ($23.68) to GBX 1,773 ($23.32) and set a “neutral” rating for the company in a research report on Thursday, February 6th. Shore Capital restated a “sell” rating on shares of GlaxoSmithKline in a research report on Wednesday. Finally, Jefferies Financial Group restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, January 20th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of GBX 1,852.87 ($24.37).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More: Portfolio Manager

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.